BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 8643525)

  • 1. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin.
    Bao J; Sharp AH; Wagster MV; Becher M; Schilling G; Ross CA; Dawson VL; Dawson TM
    Proc Natl Acad Sci U S A; 1996 May; 93(10):5037-42. PubMed ID: 8643525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
    Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
    Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular aspects of Huntington's disease.
    Walling HW; Baldassare JJ; Westfall TC
    J Neurosci Res; 1998 Nov; 54(3):301-8. PubMed ID: 9819135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntingtin-protein interactions and the pathogenesis of Huntington's disease.
    Li SH; Li XJ
    Trends Genet; 2004 Mar; 20(3):146-54. PubMed ID: 15036808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DMSO and glycerol reduce bacterial death induced by expression of truncated N-terminal huntingtin with expanded polyglutamine tracts.
    Nagao Y; Ishiguro H; Nukina N
    Biochim Biophys Acta; 2000 Oct; 1502(2):247-56. PubMed ID: 11040449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calmodulin regulates transglutaminase 2 cross-linking of huntingtin.
    Zainelli GM; Ross CA; Troncoso JC; Fitzgerald JK; Muma NA
    J Neurosci; 2004 Feb; 24(8):1954-61. PubMed ID: 14985437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
    Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
    FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin.
    Dudek NL; Dai Y; Muma NA
    Brain Pathol; 2010 Jan; 20(1):176-89. PubMed ID: 19338577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the Huntington's disease (IT15) protein product in HD patients.
    Schilling G; Sharp AH; Loev SJ; Wagster MV; Li SH; Stine OC; Ross CA
    Hum Mol Genet; 1995 Aug; 4(8):1365-71. PubMed ID: 7581375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
    Jana NR; Zemskov EA; Wang Gh ; Nukina N
    Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of Huntington disease protein with transcriptional activator Sp1.
    Li SH; Cheng AL; Zhou H; Lam S; Rao M; Li H; Li XJ
    Mol Cell Biol; 2002 Mar; 22(5):1277-87. PubMed ID: 11839795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huntington's disease gene product, huntingtin, associates with microtubules in vitro.
    Tukamoto T; Nukina N; Ide K; Kanazawa I
    Brain Res Mol Brain Res; 1997 Nov; 51(1-2):8-14. PubMed ID: 9427501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of overexpression of huntingtin proteins on mitochondrial integrity.
    Wang H; Lim PJ; Karbowski M; Monteiro MJ
    Hum Mol Genet; 2009 Feb; 18(4):737-52. PubMed ID: 19039036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease.
    Hackam AS; Singaraja R; Zhang T; Gan L; Hayden MR
    Hum Mol Genet; 1999 Jan; 8(1):25-33. PubMed ID: 9887328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential distribution of the normal and mutated forms of huntingtin in the human brain.
    Gourfinkel-An I; Cancel G; Trottier Y; Devys D; Tora L; Lutz Y; Imbert G; Saudou F; Stevanin G; Agid Y; Brice A; Mandel JL; Hirsch EC
    Ann Neurol; 1997 Nov; 42(5):712-9. PubMed ID: 9392570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
    Wyttenbach A; Swartz J; Kita H; Thykjaer T; Carmichael J; Bradley J; Brown R; Maxwell M; Schapira A; Orntoft TF; Kato K; Rubinsztein DC
    Hum Mol Genet; 2001 Aug; 10(17):1829-45. PubMed ID: 11532992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats.
    Li SH; Li XJ
    Hum Mol Genet; 1998 May; 7(5):777-82. PubMed ID: 9536080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
    Truant R; Atwal RS; Burtnik A
    Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains.
    Modregger J; DiProspero NA; Charles V; Tagle DA; Plomann M
    Hum Mol Genet; 2002 Oct; 11(21):2547-58. PubMed ID: 12354780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Huntington disease. A review].
    Bonilla E
    Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.